<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>412-PERAMPANEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Large decrease (up to two thirds) of the concentrations of perampanel

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>412-PERAMPANEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HA01" />
<ATC code="G03HB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of perampanel &gt; or = to 12 mg/day, risk of decrease of the effectiveness of the cyproterone</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>For its indication as a hormonal contraceptive: the use of another method of contraception in particular a barrier type is preferred for the length of time these substances are taken together and a cycle following</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>412-PERAMPANEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OXCARBAZEPINE" rxcui="32624">
<ATC code="N03AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease by half of the concentrations of perampanel and slight increase of those of the oxcarbazepine.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>412-PERAMPANEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG2>
<DESCRIPTION>For doses of perampanel &gt;=12 mg/day: Risk of decrease of the contraceptive effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type, should be used.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>412-PERAMPANEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease (up to two thirds) of the concentrations of perampanel</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
